ResearcherColumbia UniversityNo recent work listed

Kristin Kaley

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5044012618. Sources: OpenAlex.

Their work

Papers: 8 (first author 3, last author 2)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 9

Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: none · 2014: 2 papers · 2015: 1 paper · 2016: 3 papers

Papers 8

A novel schedule of erlotinib/capecitabine (7/7) as salvage therapy in previously treated advanced pancreatic adenocarcinoma: a case series. First author DOI 10.1177/1756283x15622779 ↗
Therapy-Associated Myeloid Dysplasia in a Long-Surviving Patient with Pancreatic Cancer. First author DOI 10.7759/cureus.687 ↗
Pancreatic Adenocarcinoma Complicated by Sinistral Portal Hypertension. First author DOI 10.7759/cureus.689 ↗
Clinical outcomes in pancreatic adenocarcinoma associated with BRCA-2 mutation. Co-author DOI 10.1097/cad.0000000000000178 ↗
First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer. Co-author DOI 10.1007/s00280-013-2359-7 ↗
Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma. Co-author DOI 10.3892/ol.2014.2238 ↗
Pancreatic adenocarcinoma with supraclavicular lymph node metastasis: is this the Virchow's node? Last author DOI 10.6092/1590-8577/3389 ↗
Cutaneous metastasis in a patient with pancreatic cancer. Last author DOI 10.6092/1590-8577/3303 ↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Muhammad Wasif Saif · 8 shared papers, 2011–2016 · strength 0.48
Lynne A. Lamb · 2 shared papers, 2014–2016 · strength 0.14
- Paper Pancreatic Adenocarcinoma Complicated by Sinistral Portal Hypertension. DOI 10.7759/cureus.689 ↗
- Paper First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients … DOI 10.1007/s00280-013-2359-7 ↗
Jillian Suzukida · 1 shared paper, 2016 · strength 0.08
- Paper Therapy-Associated Myeloid Dysplasia in a Long-Surviving Patient with Pancreatic Cancer. DOI 10.7759/cureus.687 ↗
Jiezhong Chen · 1 shared paper, 2016 · strength 0.08
- Paper A novel schedule of erlotinib/capecitabine (7/7) as salvage therapy in previously treated advanced pancreatic adenocarc… DOI 10.1177/1756283x15622779 ↗
Ojas Harihar Vyas · 1 shared paper, 2015 · strength 0.06
- Paper Clinical outcomes in pancreatic adenocarcinoma associated with BRCA-2 mutation. DOI 10.1097/cad.0000000000000178 ↗
Keith Leung · 1 shared paper, 2015 · strength 0.06
- Paper Clinical outcomes in pancreatic adenocarcinoma associated with BRCA-2 mutation. DOI 10.1097/cad.0000000000000178 ↗
Kostas Syrigos · 1 shared paper, 2014 · strength 0.05
- Paper Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma. DOI 10.3892/ol.2014.2238 ↗
Yung‐Chi Cheng · 1 shared paper, 2014 · strength 0.04
- Paper First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients … DOI 10.1007/s00280-013-2359-7 ↗
Jia Li · 1 shared paper, 2014 · strength 0.04
- Paper First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients … DOI 10.1007/s00280-013-2359-7 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.